Overview Carboplatin-cyclophosphamide Combined With Atezolizumab Status: Completed Trial end date: 2021-10-01 Target enrollment: Participant gender: Summary This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab. Phase: Phase 1 Details Lead Sponsor: The Netherlands Cancer InstituteCollaborator: Roche Pharma AGTreatments: Antibodies, MonoclonalAtezolizumabCarboplatinCyclophosphamide